FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 380 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR ESMO Launches Clinical Trials Funding Initiative to Optimise Cancer Care Pathways September 10, 2026 NBC’s Kristen Dahlgren Discusses The Unexpected Breast Cancer Symptom She Almost... December 13, 2019 Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent... March 5, 2026 Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched... May 26, 2023 Load more HOT NEWS Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma... What to Know About Kidney Cancer Genetic Conditions and Genetic Counseling Oncotype DX Breast Cancer Test May Be Less Accurate for Black... FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT...
